^
    19d
    RENEU-HF: Study of JK07 in Patients With Chronic Heart Failure (clinicaltrials.gov)
    P2, N=282, Active, not recruiting, Salubris Biotherapeutics Inc | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Oct 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    22d
    A novel mitochondrial-related signature to decode tumor immunity and predict survival in chromophobe renal cell carcinoma. (PubMed, Immunobiology)
    Notably, our computational analysis based on GDSC's pRRophetic algorithm suggests that LCL161 and UMI-77 may be more effective in the low-risk group, while sapitinib and luminespib show potential efficacy in the high-risk group. In conclusion, our study indicates this model holds high promise as a reliable biomarker for outcome prediction and precision-medicine stratification in chRCC patients.
    Journal • Tumor mutational burden
    |
    RECQL4( RecQ Like Helicase 4) • TERF1 (Telomeric Repeat Binding Factor 1)
    |
    luminespib (AUY922) • LCL161 • sapitinib (AZD8931)
    26d
    RENEU-PH: Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension (clinicaltrials.gov)
    P2, N=0, Withdrawn, Salubris Biotherapeutics Inc | N=30 --> 0 | Trial completion date: Oct 2027 --> Apr 2026 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2026 --> Apr 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    1m
    A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Novelwise Pharmaceutical Corporation
    New P1/2 trial
    |
    temozolomide
    2ms
    EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer. (PubMed, J Clin Invest)
    Izalontamab brengitecan (Iza-bren; BL-B01D1) is a bispecific ADC targeting EGFR and HER3 that has demonstrated activity in other malignancies. Importantly, tumor tissue obtained at progression after BL-B01D1 treatment confirmed ABCG2 upregulation, validating a clinically relevant resistance mechanism. These findings support BL-B01D1 as a promising therapeutic strategy in mCRPC and nominate ABCG2 as a rational target for overcoming resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    EGFR expression
    |
    izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    2ms
    Exploring prognostic genes related to lactylation and programmed cell death in pancreatic ductal adenocarcinoma: a comprehensive study combining bulk transcriptomics and experimental verification. (PubMed, Front Genet)
    Drug sensitivity analysis revealed that Sapitinib was more effective in the high-risk group (HRG), while Doramapimod was more effective in the low-risk group (LRG) (P < 0.0001)...Finally, genes in the clinical samples also showed the same expression trend. In the present investigation, two prognostic genes were identified, and subsequently, a predictive risk model was established, which may serve as a valuable reference for the clinical management of PDAC.
    Journal
    |
    HMGA1 (High Mobility Group AT-Hook 1) • KIF2C (Kinesin Family Member 2C)
    |
    sapitinib (AZD8931)
    3ms
    Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. (PubMed, J Clin Oncol)
    iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • RET fusion • EGFR exon 20 insertion • RET mutation • ROS1 fusion • MET mutation • EGFR exon 20 mutation • NTRK fusion
    |
    izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    3ms
    Construction and validation of golgi apparatus-related genes as predictors of the immune microenvironment and prognosis in colorectal cancer. (PubMed, Transl Oncol)
    Collectively, our work links GARG expression to CRC prognosis and immune features, and functionally implicates GDI1 in tumor cell aggressiveness, supporting its further study as a potential therapeutic target.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    dasatinib • sapitinib (AZD8931)
    4ms
    Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Krazati (adagrasib) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    4ms
    Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. (PubMed, Ann Oncol)
    In this exploratory post hoc pooled analysis, Iza-bren demonstrated promising antitumor activity and a manageable safety profile in heavily pretreated EGFR-mutated NSCLC. These findings are hypothesis-generating and are being further evaluated in ongoing randomized trials.
    P1 data • P2 data • Retrospective data • Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation
    |
    izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    5ms
    KIF5B-driven unfolded protein response reprograms breast cancer immunosuppressive microenvironment for single-cell guided therapeutic targeting. (PubMed, Discov Oncol)
    Our multimodal analysis establishes KIF5B as a prognostic biomarker and potential therapeutic target in BRCA, with implications for understanding immune evasion and guiding precision treatment strategies.
    Journal • BRCA Biomarker
    |
    KIF5B (Kinesin Family Member 5B) • BRCA (Breast cancer early onset)
    |
    LCL161 • sapitinib (AZD8931)
    5ms
    RENEU-PH: Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension (clinicaltrials.gov)
    P2, N=30, Recruiting, Salubris Biotherapeutics Inc | Not yet recruiting --> Recruiting
    Enrollment open